کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2116449 | 1084916 | 2010 | 8 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Novel anti-CD20 antibody TGLA with enhanced antibody-dependent cell-mediated cytotoxicity mediates potent anti-lymphoma activity
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
PVDFAnti-CD20 monoclonal antibodyCDCADCCFITCPBMCmAbPBSFCMMonoclonal antibody - آنتی بادی مونوکلونالantibody-dependent cellular cytotoxicity - آنتی بادی-وابسته به سمیت سلولی سلولیimmunotherapy - ایمونوتراپیCho - برایChinese Hamster Ovary - تخمدان هامستر چینیpolyvinylidene difluoride - دی فلوئورید پلی وینیلیدینRituximab - ریتوکسیمابperipheral blood mononuclear cells - سلول های تک هسته ای خون محیطیcomplement-dependent cytotoxicity - سمیت سلولی وابسته به مکملPhosphate buffered saline - فسفات بافر شورfluorescein isothiocyanate - فلوئورسین ایسوتیوسیاناتFlow cytometry - فلوسیتومتری
موضوعات مرتبط
علوم زیستی و بیوفناوری
بیوشیمی، ژنتیک و زیست شناسی مولکولی
تحقیقات سرطان
پیش نمایش صفحه اول مقاله

چکیده انگلیسی
Rituximab is the first anti-cancer antibody approved by the FDA for the treatment of B-cell lymphoma. However, its efficacy remains variable and often modest. Some patients are initially unresponsive to rituximab or later develop resistance to it, and require alternative therapies. Rituximab activity has been thought to involve antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and apoptosis. Present studies suggest that the patients unresponsive to rituximab may be helped with other CD20 antibodies with enhanced activities. In this study, we characterized a novel anti-CD20 chimeric antibody, TGLA, which binds to various B-cell lines specially and shares an epitope with rituximab. TGLA shows equal activities with rituximab, such as CDC, cell growth arrest and so on. Interestingly, TGLA also shows significant ADCC activity. Immunotherapeutic studies further show that TGLA is far more effective in delaying tumor growth than rituximab. These findings suggest that the ADCC-enhanced anti-CD20 antibody TGLA might be an alternative therapeutic agent for B-cell lymphoma.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Cancer Letters - Volume 294, Issue 1, 1 August 2010, Pages 66-73
Journal: Cancer Letters - Volume 294, Issue 1, 1 August 2010, Pages 66-73
نویسندگان
Ming Lv, Zhou Lin, Chunxia Qiao, Shusheng Gen, Xiaoling Lang, Yan Li, Jiannan Feng, Beifen Shen,